Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Novartis
Kivu Bioscience Inc.
National Cancer Institute (NCI)
Bayer
Actuate Therapeutics Inc.
Eastern Cooperative Oncology Group
QuantumLeap Healthcare Collaborative
FindCure Biosciences (ZhongShan) Co., Ltd.
Hoffmann-La Roche
University of California, Irvine
ViroMissile, Inc.
Dana-Farber Cancer Institute
Kaiser Permanente
University of Florida
Essen Biotech
Angiex, Inc.
MacroGenics
Avacta Life Sciences Ltd
Duke University
M.D. Anderson Cancer Center
University of Southern California
Eli Lilly and Company
Var2 Pharmaceuticals
National Institutes of Health Clinical Center (CC)
University of Illinois at Chicago
Mayo Clinic
Tanabe Pharma America, Inc.
Stella Pharma Corporation
Bayer
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Pfizer
British Columbia Cancer Agency
Washington University School of Medicine
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Washington University School of Medicine
Baylor College of Medicine
University of California, Irvine
Baxter Healthcare Corporation
OncoC4, Inc.
German Cancer Research Center
Stony Brook University
Esperas Pharma Inc.
University Health Network, Toronto
Elevation Oncology